Financing ·
Radiopharm Theranostics Limited is seeking shareholder approval at an Extraordinary General Meeting on September 11…
RADXRadiopharm Theranostics Ltd
Radiopharm Theranostics Limited is seeking shareholder approval at an Extraordinary General Meeting on September 11, 2026, for a capital raise totaling approximately $18.5 million. The transaction includes ratifying the prior issuance of 408,839,531 placement shares and 384,493,800 ADS shares, approving up to 40,000,000 second tranche placement shares at $0.015 per share, and issuing attaching options with a $0.018 exercise price. The raise also involves a Shareholder Participation Plan for up to 666,666,667 shares capped at $10 million, alongside warrants for US subscribers and agent compensation. Funds will support drug manufacturing, clinical trials, and working capital. Radiopharm Theranostics Limited operates in the biotechnology industry, focusing on radiopharmaceuticals for theranostic applications.